Company profile for Corvidia Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Corvidia Therapeutics is a clinical stage company focused on the research, development and commercialization of transformative therapies for cardio-renal diseases. After receiving seed funding from Sofinnova Partners in 2015, our company was founded around a pipeline of assets with best in class potential to make a positive impact on patients with cardio-renal diseases. Since then, we have raised $26 million in Series A fin...
Corvidia Therapeutics is a clinical stage company focused on the research, development and commercialization of transformative therapies for cardio-renal diseases. After receiving seed funding from Sofinnova Partners in 2015, our company was founded around a pipeline of assets with best in class potential to make a positive impact on patients with cardio-renal diseases. Since then, we have raised $26 million in Series A financing led by Sofinnova Partners and Apple Tree Partners and, $60 million in Series B financing led by Venrock which included Andera Partners, Cormorant Asset Management, HBM Partners & Fresenius Medical Care Ventures.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
35 Gatehouse Drive Waltham, MA 02451
Telephone
Telephone
1-781-205-4755
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/abcentra-appoints-entrepreneur-and-cardiologist-michael-h-davidson-to-board-of-directors-301398845.html

PRNEWSWIRE
14 Oct 2021

https://endpts.com/after-novo-nordisks-acquisition-of-corvidia-ram-aiyar-takes-the-helm-at-korro-bio-silverback-gets-a-new-cfo-to-go-along-with-its-ipo/

Alex Hoffman ENDPTS
13 Nov 2020
Bermingham's Korro Bio lands ex-Corvidia executive as CEO
Bermingham's Korro Bio lands ex-Corvidia executive as CEO

11 Nov 2020

// Amirah Al Idrus FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/bermingham-s-korro-bio-lands-ex-corvidia-executive-as-ceo

Amirah Al Idrus FIERCE BIOTECH
11 Nov 2020

https://www.businesswire.com/news/home/20200611005512/en/Sofinnova-Partners-Announces-Sale-Corvidia-Therapeutics-Novo

BUSINESSWIRE
12 Jun 2020

https://thefly.com/landingPageNews.php?id=3109046&headline=NVO-Novo-Nordisk-to-acquire-Corvidia-Therapeutics-to-expand-cardiovascular-presence

THEFLY
10 Jun 2020

https://www.sttinfo.fi/tiedote/sofinnova-partners-announces-sale-of-corvidia-therapeutics-to-novo-nordisk?publisherId=58763726&releaseId=69883412

STTINFO
10 Jun 2020

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty